{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:03:00Z","timestamp":1791669780446,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Jilin Provincial Scientific and Technological Development Program","award":["20220401062YY"],"award-info":[{"award-number":["20220401062YY"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91463-5","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T16:41:34Z","timestamp":1741365694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database"],"prefix":"10.1038","volume":"15","author":[{"given":"Yongfu","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tieshi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"91463_CR1","doi-asserted-by":"publisher","first-page":"175346661881019","DOI":"10.1177\/1753466618810192","volume":"12","author":"C Pelaia","year":"2018","unstructured":"Pelaia, C. et al. Omalizumab, the first available antibody for biological treatment of severe asthma: More than a decade of real-life effectiveness. Ther. Adv. Respir. Dis. 12, 1753466618810192 (2018).","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"5","key":"91463_CR2","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jaip.2019.02.030","volume":"7","author":"M Humbert","year":"2019","unstructured":"Humbert, M. et al. IgE-mediated multimorbidities in allergic asthma and the potential for omalizumab therapy. J. Allergy Clin. Immunol. Pract. 7(5), 1418\u20131429 (2019).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"12","key":"91463_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11882-022-01048-9","volume":"22","author":"TG Chow","year":"2022","unstructured":"Chow, T. G., Franzblau, L. E. & Khan, D. A. Adverse reactions to biologic medications used in allergy and immunology diseases. Curr. Allergy Asthma Rep. 22(12), 195\u2013207 (2022).","journal-title":"Curr. Allergy Asthma Rep."},{"key":"91463_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/JAA.S288952","volume":"14","author":"T Ma","year":"2021","unstructured":"Ma, T., Wang, H. & Wang, X. Effectiveness and response predictors of omalizumab in treating patients with seasonal allergic rhinitis: A real-world study. J. Asthma Allergy. 14, 59\u201366 (2021).","journal-title":"J. Asthma Allergy."},{"issue":"1","key":"91463_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","volume":"174","author":"S Chan","year":"2020","unstructured":"Chan, S., Cornelius, V., Cro, S., Harper, J. I. & Lack, G. Treatment effect of omalizumab on severe pediatric atopic dermatitis: The ADAPT randomized clinical trial. JAMA Pediatr. 174(1), 29\u201337 (2020).","journal-title":"JAMA Pediatr."},{"issue":"8","key":"91463_CR6","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1111\/all.15807","volume":"78","author":"YH Shin","year":"2023","unstructured":"Shin, Y. H. et al. Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. Allergy. 78(8), 2232\u20132254 (2023).","journal-title":"Allergy."},{"issue":"3","key":"91463_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1183\/9031936.00.16337700","volume":"16","author":"N Pearce","year":"2000","unstructured":"Pearce, N. et al. Comparison of asthma prevalence in the ISAAC and the ECRHS. ISAAC steering committee and the European community respiratory health survey. International study of asthma and allergies in childhood. Eur. Respir. J. 16(3), 420\u2013426 (2000).","journal-title":"Eur. Respir. J."},{"issue":"3","key":"91463_CR8","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/crj.12655","volume":"12","author":"A Alavinezhad","year":"2018","unstructured":"Alavinezhad, A. & Boskabady, M. H. The prevalence of asthma and related symptoms in Middle East countries. Clin. Respir. J. 12(3), 865\u2013877 (2018).","journal-title":"Clin. Respir. J."},{"issue":"6","key":"91463_CR9","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/all.15600","volume":"78","author":"MJ Koo","year":"2023","unstructured":"Koo, M. J. et al. National trends in the prevalence of allergic diseases among Korean adolescents before and during COVID-19, 2009\u20132021: A serial analysis of the national representative study. Allergy. 78(6), 1665\u20131670 (2023).","journal-title":"Allergy."},{"issue":"9","key":"91463_CR10","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1164\/rccm.201901-0016OC","volume":"200","author":"M Yaghoubi","year":"2019","unstructured":"Yaghoubi, M., Adibi, A., Safari, A., FitzGerald, J. M. & Sadatsafavi, M. The projected economic and health burden of uncontrolled asthma in the United States. Am. J. Respir. Crit. Care Med. 200(9), 1102\u20131112 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"91463_CR11","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/all.14235","volume":"75","author":"I Agache","year":"2020","unstructured":"Agache, I. et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 75(5), 1043\u20131057 (2020).","journal-title":"Allergy."},{"issue":"5","key":"91463_CR12","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/all.14221","volume":"75","author":"I Agache","year":"2020","unstructured":"Agache, I. et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 75(5), 1023\u20131042 (2020).","journal-title":"Allergy."},{"issue":"3","key":"91463_CR13","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jaci.2017.10.018","volume":"141","author":"M Maurer","year":"2018","unstructured":"Maurer, M. et al. The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria. J. Allergy Clin. Immunol. 141(3), 1138\u20139.e7 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"91463_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","volume":"154","author":"NA Hanania","year":"2011","unstructured":"Hanania, N. A. et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial. Ann. Intern. Med. 154(9), 573\u2013582 (2011).","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"91463_CR15","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1183\/09031936.00008115","volume":"46","author":"A Deschildre","year":"2015","unstructured":"Deschildre, A. et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur. Respir. J. 46(3), 856\u2013859 (2015).","journal-title":"Eur. Respir. J."},{"key":"91463_CR16","doi-asserted-by":"publisher","first-page":"1489045","DOI":"10.3389\/fphar.2024.1489045","volume":"15","author":"M Peng","year":"2024","unstructured":"Peng, M. et al. A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases. Front. Pharmacol. 15, 1489045 (2024).","journal-title":"Front. Pharmacol."},{"key":"91463_CR17","doi-asserted-by":"publisher","first-page":"894685","DOI":"10.3389\/fphar.2022.894685","volume":"13","author":"Z Feng","year":"2022","unstructured":"Feng, Z. et al. Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS. Front. Pharmacol. 13, 894685 (2022).","journal-title":"Front. Pharmacol."},{"issue":"7","key":"91463_CR18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10(7), 796\u2013803 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"91463_CR19","doi-asserted-by":"publisher","first-page":"1485067","DOI":"10.3389\/fphar.2024.1485067","volume":"15","author":"H Ke","year":"2024","unstructured":"Ke, H. et al. Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess. Front. Pharmacol. 15, 1485067 (2024).","journal-title":"Front. Pharmacol."},{"issue":"5","key":"91463_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster, O., Aoki, Y., Gattepaille, L. M. & Grundmark, B. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: Recommendations for limiting false-positive associations. Drug Saf. 43(5), 479\u2013487 (2020).","journal-title":"Drug Saf."},{"issue":"6","key":"91463_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc, J. L., Sommet, A., Bagheri, H. & Lapeyre-Mestre, M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br. J. Clin. Pharmacol. 72(6), 905\u2013908 (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"91463_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13(8), 519\u2013523 (2004).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"6","key":"91463_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10(6), 483\u2013486 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"91463_CR24","doi-asserted-by":"publisher","first-page":"1200254","DOI":"10.3389\/fphar.2023.1200254","volume":"14","author":"Y Wu","year":"2023","unstructured":"Wu, Y., Wei, M. & Zhang, J. A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib. Front. Pharmacol. 14, 1200254 (2023).","journal-title":"Front. Pharmacol."},{"key":"91463_CR25","doi-asserted-by":"publisher","first-page":"970066","DOI":"10.3389\/fphar.2022.970066","volume":"13","author":"S Tang","year":"2022","unstructured":"Tang, S., Wu, Z., Xu, L., Wen, Q. & Zhang, X. Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS. Front. Pharmacol. 13, 970066 (2022).","journal-title":"Front. Pharmacol."},{"key":"91463_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40780-018-0109-z","volume":"4","author":"Y Noguchi","year":"2018","unstructured":"Noguchi, Y. et al. Signals of gastroesophageal reflux disease caused by incretin-based drugs: A disproportionality analysis using the Japanese adverse drug event report database. J. Pharm. Health Care Sci. 4, 15 (2018).","journal-title":"J. Pharm. Health Care Sci."},{"key":"91463_CR27","doi-asserted-by":"publisher","first-page":"103828","DOI":"10.1016\/j.ajp.2023.103828","volume":"90","author":"Q Zhou","year":"2023","unstructured":"Zhou, Q. et al. Adverse events of epidiolex: A real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database. Asian J. Psychiatr. 90, 103828 (2023).","journal-title":"Asian J. Psychiatr."},{"issue":"5","key":"91463_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40264-020-00913-8","volume":"43","author":"ST de Vries","year":"2020","unstructured":"de Vries, S. T., Denig, P., Ekhart, C., Mol, P. G. M. & van Puijenbroek, E. P. Sex differences in adverse drug reactions of metformin: A longitudinal survey study. Drug Saf. 43(5), 489\u2013495 (2020).","journal-title":"Drug Saf."},{"key":"91463_CR29","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","volume":"14","author":"F Zou","year":"2023","unstructured":"Zou, F. et al. A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database. Front. Pharmacol. 14, 1320458 (2023).","journal-title":"Front. Pharmacol."},{"issue":"2","key":"91463_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/00325481.2018.1430447","volume":"130","author":"G Ciprandi","year":"2018","unstructured":"Ciprandi, G. & Gallo, F. The impact of gender on asthma in the daily clinical practice. Postgrad. Med. 130(2), 271\u2013273 (2018).","journal-title":"Postgrad. Med."},{"key":"91463_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020328","author":"MM Sirufo","year":"2022","unstructured":"Sirufo, M. M., De Pietro, F., Ginaldi, L. & De Martinis, M. Sex, Allergic diseases and omalizumab. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10020328 (2022).","journal-title":"Biomedicines"},{"issue":"9","key":"91463_CR32","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.celrep.2017.10.110","volume":"21","author":"JY Cephus","year":"2017","unstructured":"Cephus, J. Y. et al. Testosterone attenuates group 2 innate lymphoid cell-mediated airway inflammation. Cell Rep. 21(9), 2487\u20132499 (2017).","journal-title":"Cell Rep."},{"issue":"4","key":"91463_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/ni.3371","volume":"17","author":"EJ Carr","year":"2016","unstructured":"Carr, E. J. et al. The cellular composition of the human immune system is shaped by age and cohabitation. Nat. Immunol. 17(4), 461\u2013468 (2016).","journal-title":"Nat. Immunol."},{"key":"91463_CR34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fimmu.2013.00316","volume":"4","author":"DB Palmer","year":"2013","unstructured":"Palmer, D. B. The effect of age on thymic function. Front. Immunol. 4, 316 (2013).","journal-title":"Front. Immunol."},{"issue":"6","key":"91463_CR35","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","volume":"120","author":"L Cox","year":"2007","unstructured":"Cox, L. et al. American academy of allergy, asthma & immunology\/american college of allergy, asthma and immunology joint task force report on omalizumab-associated anaphylaxis. J. Allergy Clin. Immunol. 120(6), 1373\u20131377 (2007).","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"91463_CR36","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1249\/MSS.0b013e318193c663","volume":"41","author":"M Bonini","year":"2009","unstructured":"Bonini, M. et al. Aqua allergy questionnaire for athletes. Development and validation. Med. Sci. Sports Exerc. 41(5), 1034\u20131041 (2009).","journal-title":"Med. Sci. Sports Exerc."},{"issue":"3","key":"91463_CR37","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","volume":"139","author":"AJ MacGinnitie","year":"2017","unstructured":"MacGinnitie, A. J. et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J. Allergy Clin. Immunol. 139(3), 873\u201381.e8 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"91463_CR38","doi-asserted-by":"publisher","first-page":"e12038","DOI":"10.1002\/clt2.12038","volume":"11","author":"L Li","year":"2021","unstructured":"Li, L. et al. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab. Clin. Transl. Allergy. 11(4), e12038 (2021).","journal-title":"Clin. Transl. Allergy."},{"issue":"1","key":"91463_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/all.14425","volume":"76","author":"I Agache","year":"2021","unstructured":"Agache, I. et al. EAACI Biologicals Guidelines-Recommendations for severe asthma. Allergy. 76(1), 14\u201344 (2021).","journal-title":"Allergy."},{"issue":"3","key":"91463_CR40","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1365-2567.2006.02390.x","volume":"118","author":"D Kozutsumi","year":"2006","unstructured":"Kozutsumi, D. et al. PS80 interferes with the antiallergic effect of Cry-consensus peptide, a novel recombinant peptide for immunotherapy of Japanese cedar pollinosis, at very low concentration through modulation of Th1\/Th2 balance. Immunology. 118(3), 392\u2013401 (2006).","journal-title":"Immunology."},{"issue":"3","key":"91463_CR41","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1440-1797.2005.00389.x","volume":"10","author":"RH Steele","year":"2005","unstructured":"Steele, R. H., Limaye, S., Cleland, B., Chow, J. & Suranyi, M. G. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrol. (Carlton). 10(3), 317\u2013320 (2005).","journal-title":"Nephrol. (Carlton)."},{"issue":"3","key":"91463_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2500\/aap.2007.28.3003","volume":"28","author":"KS Price","year":"2007","unstructured":"Price, K. S. & Hamilton, R. G. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc. 28(3), 313\u2013319 (2007).","journal-title":"Allergy Asthma Proc."},{"issue":"3","key":"91463_CR43","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/all.14027","volume":"75","author":"S Eyerich","year":"2020","unstructured":"Eyerich, S., Metz, M., Bossios, A. & Eyerich, K. New biological treatments for asthma and skin allergies. Allergy. 75(3), 546\u2013560 (2020).","journal-title":"Allergy."},{"issue":"8","key":"91463_CR44","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1177\/0192623318797070","volume":"46","author":"JL Vahle","year":"2018","unstructured":"Vahle, J. L. Immunogenicity and immune complex disease in preclinical safety studies. Toxicol. Pathol. 46(8), 1013\u20131019 (2018).","journal-title":"Toxicol. Pathol."},{"key":"91463_CR45","doi-asserted-by":"publisher","first-page":"1276340","DOI":"10.3389\/fphar.2023.1276340","volume":"14","author":"V Pera","year":"2023","unstructured":"Pera, V. et al. Parasitic infections related to anti-type 2 immunity monoclonal antibodies: A disproportionality analysis in the food and drug administration\u2019s adverse event reporting system (FAERS). Front. Pharmacol. 14, 1276340 (2023).","journal-title":"Front. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91463-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91463-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91463-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T17:21:40Z","timestamp":1741368100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91463-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91463"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91463-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study utilized anonymous data sourced from an open-access database, thereby obviating the need for institutional ethical approval and written informed consent from participants or their legal guardians\/relatives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8045"}}